HK1057211A1 - Aryl oxime-piperazines useful as ccr5 antagonists - Google Patents

Aryl oxime-piperazines useful as ccr5 antagonists

Info

Publication number
HK1057211A1
HK1057211A1 HK04100067.4A HK04100067A HK1057211A1 HK 1057211 A1 HK1057211 A1 HK 1057211A1 HK 04100067 A HK04100067 A HK 04100067A HK 1057211 A1 HK1057211 A1 HK 1057211A1
Authority
HK
Hong Kong
Prior art keywords
ccr5 antagonists
aryl oxime
piperazines useful
piperazines
useful
Prior art date
Application number
HK04100067.4A
Other languages
English (en)
Inventor
John W Clader
Sue-Ing Y Lin
Stuart W Mccombie
Pradeep B Pushpavanam
Susan Vice
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of HK1057211A1 publication Critical patent/HK1057211A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK04100067.4A 2001-03-29 2004-01-06 Aryl oxime-piperazines useful as ccr5 antagonists HK1057211A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27995001P 2001-03-29 2001-03-29
PCT/US2002/009490 WO2002079157A1 (fr) 2001-03-29 2002-03-27 Aryloxime-piperazines utiles comme antagonistes de ccr5

Publications (1)

Publication Number Publication Date
HK1057211A1 true HK1057211A1 (en) 2004-03-19

Family

ID=23071025

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04100067.4A HK1057211A1 (en) 2001-03-29 2004-01-06 Aryl oxime-piperazines useful as ccr5 antagonists

Country Status (19)

Country Link
US (1) US6689783B2 (fr)
EP (1) EP1373206B1 (fr)
JP (1) JP4303969B2 (fr)
KR (1) KR20030083015A (fr)
CN (1) CN1253435C (fr)
AR (1) AR033622A1 (fr)
AT (1) ATE418542T1 (fr)
AU (1) AU2002303168B2 (fr)
CA (1) CA2442210C (fr)
DE (1) DE60230491D1 (fr)
ES (1) ES2318009T3 (fr)
HK (1) HK1057211A1 (fr)
HU (1) HUP0400389A3 (fr)
IL (1) IL157713A0 (fr)
MX (1) MXPA03008801A (fr)
MY (1) MY134019A (fr)
NZ (1) NZ528011A (fr)
WO (1) WO2002079157A1 (fr)
ZA (1) ZA200307171B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7825121B2 (en) * 1999-05-04 2010-11-02 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
PE20040769A1 (es) * 2002-12-18 2004-11-06 Schering Corp Derivados de piperidina utiles como antagonisas ccr5
US7705153B2 (en) * 2004-02-05 2010-04-27 Schering Corporation Bipiperdine derivatives useful as CCR3 antagonists
US7678798B2 (en) 2004-04-13 2010-03-16 Incyte Corporation Piperazinylpiperidine derivatives as chemokine receptor antagonists
US20070215685A1 (en) * 2005-02-03 2007-09-20 Yottamark, Inc. System and Method of Product Identification Using a URL
JP4769257B2 (ja) * 2005-02-23 2011-09-07 シェーリング コーポレイション ケモカインレセプターのインヒビターとして有用なピペリジニルピペラジン誘導体
WO2008030853A2 (fr) * 2006-09-06 2008-03-13 Incyte Corporation Thérapie de combinaison contre l'infection par le virus de l'immunodéficience humaine
KR100830003B1 (ko) * 2006-10-31 2008-05-15 씨제이제일제당 (주) 결정성 ｓ-(-)-암로디핀 아디핀산 염 무수물 및 이의 제조방법
US20080173808A1 (en) * 2007-01-18 2008-07-24 Schering Corporation Process and device for response normalized liquid chromatography nanospray ionization mass spectrometry (rnlc-nsi-ms)
EP2741777B1 (fr) 2011-08-12 2017-01-18 INSERM - Institut National de la Santé et de la Recherche Médicale Procédés et compositions pharmaceutiques pour le traitement de l'hypertension pulmonaire
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4949314A (en) 1966-08-16 1990-08-14 The United States Of America As Represented By The Secretary Of The Navy Method and means for increasing echo-ranging-search rate
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
GB8327880D0 (en) 1983-10-18 1983-11-16 Ajinomoto Kk Saccharomyces cerevisiae
US4569790A (en) 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4604377A (en) 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US4530787A (en) 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
IL76360A0 (en) 1984-09-26 1986-01-31 Takeda Chemical Industries Ltd Mutual separation of proteins
US4748234A (en) 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
NZ230045A (en) * 1988-08-05 1990-11-27 Janssen Pharmaceutica Nv 3-piperazinylbenzazole derivatives and pharmaceutical compositions
US5368854A (en) 1992-08-20 1994-11-29 Schering Corporation Use of IL-10 to treat inflammatory bowel disease
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
CA2212370A1 (fr) 1995-02-16 1996-08-22 Moses Judah Folkman Inhibition de l'angiogenese a l'aide de l'interleukine-12
WO2000066558A1 (fr) * 1999-05-04 2000-11-09 Schering Corporation Derives de piperazine faisant office d'antagonistes ccr5

Also Published As

Publication number Publication date
CN1253435C (zh) 2006-04-26
US20030087912A1 (en) 2003-05-08
ES2318009T3 (es) 2009-05-01
WO2002079157A1 (fr) 2002-10-10
ZA200307171B (en) 2004-12-13
AR033622A1 (es) 2003-12-26
JP4303969B2 (ja) 2009-07-29
CA2442210A1 (fr) 2002-10-10
MY134019A (en) 2007-11-30
ATE418542T1 (de) 2009-01-15
MXPA03008801A (es) 2004-02-18
NZ528011A (en) 2004-08-27
CN1500078A (zh) 2004-05-26
CA2442210C (fr) 2009-09-08
US6689783B2 (en) 2004-02-10
DE60230491D1 (de) 2009-02-05
KR20030083015A (ko) 2003-10-23
JP2004524360A (ja) 2004-08-12
AU2002303168B2 (en) 2005-10-06
HUP0400389A3 (en) 2008-03-28
IL157713A0 (en) 2004-03-28
EP1373206A1 (fr) 2004-01-02
HUP0400389A2 (hu) 2004-08-30
EP1373206B1 (fr) 2008-12-24

Similar Documents

Publication Publication Date Title
LU92759I2 (en) Vorapaxar ou son sel solvat pharmacologiquement admissible
HK1083505A1 (en) Ccr5 antagonists useful for treating aids
PL356034A1 (en) Cyclic amine compounds as ccr5 antagonists
EP1451173A4 (fr) Piperidines
AU2002341834A1 (en) Antagonists
IL165841A0 (en) Mchir antagonists
IL160060A0 (en) Piperidine derivatives useful as ccr5 antagonists
IL158517A0 (en) Novel 4-anilinoquinoline-3-carboxamides
GB0118573D0 (en) Flag stone
PL372295A1 (en) Quinoline derivatives as npy antagonists
PL376509A1 (en) Antagonists il-15
AU2002350244A8 (en) Pyridoquinoxaline antivirals
HK1063791A1 (en) Nk1 antagonists
GB0104948D0 (en) Novel methods
IL157713A0 (en) Aryl oxime-piperazines useful as ccr5 antagonists
EP1384783A4 (fr) Nouveau maxizyme
GB0304653D0 (en) Acetylcholinesterase assay
IL162534A0 (en) Novel alkansulfonamides as endotheline antagonists
PL364076A1 (en) Novel pyridylmethylaminopyrimidines
DE60239047D1 (en) Humaner g-protein-chemokinrezeptor (ccr5) hdgnr10
CA94574S (en) Pot
AU2002360933A1 (en) Antagonists for alpha4-integrins
GB0227069D0 (en) Suporta pot
AU149809S (en) Pot
GB0124684D0 (en) Tile

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130327